Облигации: Intercept Pharmaceuticals, 2% 15may2026, USD (Conv.) (FIGI BBG00P4GND55, WKN A2R2ER)
Конвертируемые, Trace-eligible, Senior Unsecured
Конвертируемые, Trace-eligible, Senior Unsecured
|
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease ...
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
|
|
|
|
|
|
|
|
|
Откройте глобальную базу данных
1 000 000
облигаций
80 234
акций
168 394
ETF & Funds
80 000
индексов
Отслеживайте свой портфель наиболее эффективным способом
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |